Red yeast rice.

Red yeast rice's monacolin K supports normal cholesterol metabolism by slowing the HMG-CoA reductase step, the same early pathway the body uses to make its own coenzyme Q10, so this activity can lower how much CoQ10 the body produces. Taking CoQ10 alongside replenishes what that shared pathway makes less of.

Monacolin K acts on the HMG-CoA reductase step that governs how much cholesterol the body builds, while berberine supports clearance of cholesterol already in circulation by increasing LDL-receptor activity through a separate pathway. Because the two support healthy lipid handling at different points, they are a long-standing formulation pairing.

Bergamot polyphenols support the body's normal cholesterol and fat metabolism through mechanisms that only partly overlap with monacolin K's action on HMG-CoA reductase. That partial overlap is why the two are commonly formulated together for lipid support.

Monacolin K inhibits HMG-CoA reductase, the same early step that supplies the farnesyl units used to build the ubiquinone tail. Ubiquinol is the reduced form of that molecule, so supplying it covers the branch the inhibition also slows.

Niacin acts on hepatic VLDL output and adipose lipolysis, a different point from the cholesterol synthesis step monacolin K inhibits. It is equally well described that the two together raise the chance of muscle complaints, so the combination needs care.

Plant sterols displace cholesterol from intestinal micelles and reduce how much is absorbed, while monacolin K reduces how much the liver makes. The two act on opposite ends of cholesterol balance and are routinely combined for that reason.

Viscous oat beta-glucan traps bile acids so more are excreted, pulling hepatic cholesterol into new bile acid synthesis. That is a separate lever from inhibiting HMG-CoA reductase, so the two stack.

Psyllium forms a gel that binds bile acids in the small intestine and increases their faecal loss. The liver then draws on cholesterol to replace them, complementing the synthesis step monacolin K slows.

EPA and DHA reduce hepatic VLDL triglyceride assembly and raise fatty acid oxidation, which is a different arm of lipid metabolism from cholesterol synthesis. Pairing them addresses both arms in one formula.

Guggulsterones act as antagonists at the farnesoid X receptor, changing bile acid and lipid gene expression. That is a transcriptional lever, distinct from direct enzyme inhibition.

Monacolin K is a CYP3A4 substrate cleared in the liver, and silymarin flavonolignans modestly inhibit CYP3A4 and some drug transporters. Taken together the monacolin exposure runs higher than the label dose implies.

Hyperforin is a potent PXR agonist that induces CYP3A4 and P-glycoprotein, and monacolin K is a CYP3A4 substrate. Taken together, the botanical clears the monacolin faster and the formula delivers less than the label implies.

Natto-derived and Monascus-derived preparations are combined in commercial products and have now been examined together in the cardiovascular literature. The two act by unrelated routes, one on fibrin handling and one on cholesterol synthesis. A 2026 commentary in JACC Asia discusses the evidence for the pairing.

Artichoke leaf increases bile flow and its cynarin fraction has been described as affecting hepatic cholesterol handling. Monacolin-containing fermented rice acts earlier, at HMG-CoA reductase. Formulators pair them because the routes differ. The combination itself has not been trialled here.

Soluble pectin binds bile acids in the gut lumen and increases their faecal loss, which pulls hepatic cholesterol into new bile acid synthesis. That is a different point in the same loop from where monacolins act. Combining a lumen-acting fibre with a synthesis-step ingredient is standard formulation logic for supporting normal blood lipid levels.

Glucomannan forms a viscous gel that slows mixed micelle formation and traps bile acids, reducing their reabsorption in the ileum. Red yeast rice works upstream in the liver. The two do not compete for the same step.

Aged garlic preparations supply S-allylcysteine, which has been described as modulating hepatic lipid handling by a route separate from HMG-CoA reductase. The combination appears in commercial cardiovascular blends. Effect sizes for the pair have not been measured together.

Catechins interfere with micellar solubilisation of cholesterol in the intestinal lumen, limiting how much is absorbed. Monacolins act on endogenous synthesis instead. Both green tea extract and Monascus preparations carry their own hepatic monitoring considerations, so a formulator combining them should say so on the label.

Tocotrienols lower HMG-CoA reductase activity by promoting degradation of the enzyme protein, which is a different control point from the competitive active-site inhibition monacolin K exerts. Acting on the same enzyme by two routes can be additive or can blunt one another, and that has not been resolved in humans. Read this as mechanistic rather than clinical.

Alpha-lipoic acid recycles other redox-active molecules and participates in mitochondrial dehydrogenase complexes. It appears in cardiometabolic blends alongside Monascus preparations. The rationale is mechanistic and no combination trial supports it.

Carnitine shuttles long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation, a fat-handling route separate from cholesterol synthesis. Blends aimed at normal lipid metabolism often include both. Nothing has tested them together.

Grape seed proanthocyanidins are described as supporting normal endothelial function through nitric oxide availability. That sits alongside rather than within the cholesterol synthesis pathway monacolins act on. The pairing is formulation convention.

Alpha-linolenic acid from flaxseed affects hepatic triglyceride handling, a different lipid fraction from the one monacolins act on most. Products aiming at the whole lipid panel often carry both. The combination has not been measured as a pair.

Chromium is discussed as supporting normal insulin signalling, and blood lipid and glucose handling are linked in the same hepatic pathways. Nutraceutical combinations aimed at both have been described in the recent literature. Evidence for chromium's own effect size is inconsistent, so this stays Early.

Quercetin inhibits CYP3A4 in vitro, and monacolin K is a CYP3A4 substrate in its lactone form. Slowing that clearance would raise systemic exposure to the monacolin. The interaction has been characterised in vitro rather than in people, and it is a reason to check the pairing rather than to assume it is additive.

Resveratrol inhibits several CYP enzymes including CYP3A4 in laboratory systems, the route that clears monacolin K. Direction and size in a person are unknown. Flag it as an interaction to watch rather than a benefit.

Menaquinone-7 carboxylates matrix Gla protein, which is the mechanism by which vitamin K status relates to normal arterial calcium handling. That runs alongside cholesterol synthesis rather than through it. The two are combined in cardiovascular blends on mechanistic grounds only.